Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Renal anemia is a common and sometimes difficult-to-manage complication in peritoneal dialysis (PD) patients. Hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors are a novel therapeutic option, but data in PD patients remain limited. This study retrospectively evaluated the efficacy of HIF-PHD inhibitors in PD patients who had been switched from erythropoiesis-stimulating agents (ESAs).
This single-center retrospective study was conducted at Narita Memorial Hospital in Aichi, Japan. Among 49 PD patients treated with HIF-PHD inhibitors daprodustat or vadadustat, 15 patients met the inclusion criteria:(1) switched from ESA therapy (patients with prior HIF-PHD inhibitor or without prior ESA use were excluded) and (2) baseline Hb < 11 g/dL. Hemoglobin levels were evaluated monthly for 5 months after initiation. A subgroup analysis was also conducted in patients with baseline Hb < 10 g/dL.
The study included 15 PD patients (7 men, 8 women; mean age, 67 ± 11 years, range 50–87 years). Mean hemoglobin increased from 9.8 ± 0.8 g/dL at baseline to 10.7 ± 1.2 g/dL at month 4, with significant improvements observed at months 3 and 4 (p = 0.0497 and 0.028, respectively).In the subgroup with baseline Hb < 10 g/dL (n = 7) Hb rose from 9.0 ± 0.6 g/dL at baseline to over 10.3 g/dL from month 3 (p = 0.031) onward with significant increases at months 3–5.
PD patients with renal anemia switched from ESA therapy HIF-PHD inhibitors significantly improved hemoglobin levels over 5 months. The improvement was particularly evident among those with baseline Hb < 10 g/dL. These findings support the clinical utility of HIF-PHD inhibitors as an effective alternative to ESA therapy in PD populations though larger prospective studies are warranted.
